Scholarlink

<p>N6-methyladenosine (m<sup>6</sup>A), the most abundant modification in eukaryotic RNAs, plays a critical role in regulating RNA stability, expression, and translation. Key m<sup>6</sup>A regulators are up- or down-regulated in human gastric cancer tissues, by <i>Helicobacter pylori</i> and transcription factors, and the aberrant expression is associated with poor patient prognosis. Dynamic m<sup>6</sup>A modification, orchestrated by methyltransferases, demethylases, and m<sup>6</sup>A-binding proteins, profoundly impacts gastric cancer tumorigenesis, metastasis, cancer cell stemness, immune evasion, and resistance to chemotherapy, radiotherapy, and immunotherapy. While aberrant m<sup>6</sup>A modifications and the expression levels of its regulatory factors in blood samples are novel biomarkers in gastric cancer patients, therapies targeting m<sup>6</sup>A regulators have emerged as promising approaches for treating the disease. In summary, m<sup>6</sup>A RNA methylation represents a pivotal epitranscriptomic mechanism with significant implications for gastric cancer biology and precision oncology.</p> Graphical Abstract <p>RNA m<sup>6</sup>A modification plays a critical role in regulating RNA stability/decay, expression, and translation. m<sup>6</sup>A methyltransferases, demethylases and binding proteins are required for gastric cancer tumorigenesis, metastasis, immune evasion, and resistance to anticancer therapies.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

RNA m6A modification is a driver and therapeutic target in gastric cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月14日

查看全文
  • Qingjuan Chen,
  • Hongzhao Lu,
  • Dezhi Li,
  • Tao Liu

摘要

N6-methyladenosine (m6A), the most abundant modification in eukaryotic RNAs, plays a critical role in regulating RNA stability, expression, and translation. Key m6A regulators are up- or down-regulated in human gastric cancer tissues, by Helicobacter pylori and transcription factors, and the aberrant expression is associated with poor patient prognosis. Dynamic m6A modification, orchestrated by methyltransferases, demethylases, and m6A-binding proteins, profoundly impacts gastric cancer tumorigenesis, metastasis, cancer cell stemness, immune evasion, and resistance to chemotherapy, radiotherapy, and immunotherapy. While aberrant m6A modifications and the expression levels of its regulatory factors in blood samples are novel biomarkers in gastric cancer patients, therapies targeting m6A regulators have emerged as promising approaches for treating the disease. In summary, m6A RNA methylation represents a pivotal epitranscriptomic mechanism with significant implications for gastric cancer biology and precision oncology.

Graphical Abstract

RNA m6A modification plays a critical role in regulating RNA stability/decay, expression, and translation. m6A methyltransferases, demethylases and binding proteins are required for gastric cancer tumorigenesis, metastasis, immune evasion, and resistance to anticancer therapies.